Results
|
|
1.
|
|
|
|
2.
|
|
|
|
3.
|
|
|
|
4.
|
Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial. [electronic resource] by
- Le Tourneau, Christophe
- Hoimes, Christopher
- Zarwan, Corrine
- Wong, Deborah J
- Bauer, Sebastian
- Claus, Rainer
- Wermke, Martin
- Hariharan, Subramanian
- von Heydebreck, Anja
- Kasturi, Vijay
- Chand, Vikram
- Gulley, James L
Producer: 20191025
In:
Journal for immunotherapy of cancer vol. 6
Availability: No items available.
|
|
|
5.
|
Phase II study of afatinib, an irreversible ErbB family blocker, in demographically and genotypically defined lung adenocarcinoma. [electronic resource] by
- De Grève, Jacques
- Moran, Teresa
- Graas, Marie-Pascale
- Galdermans, Daniella
- Vuylsteke, Peter
- Canon, Jean-Luc
- Schallier, Denis
- Decoster, Lore
- Teugels, Erik
- Massey, Dan
- Chand, Vikram K
- Vansteenkiste, Johan
Producer: 20151201
In:
Lung cancer (Amsterdam, Netherlands) vol. 88
Availability: No items available.
|
|
|
6.
|
Continued use of afatinib with the addition of cetuximab after progression on afatinib in patients with EGFR mutation-positive non-small-cell lung cancer and acquired resistance to gefitinib or erlotinib. [electronic resource] by
- Horn, Leora
- Gettinger, Scott
- Camidge, D Ross
- Smit, Egbert F
- Janjigian, Yelena Y
- Miller, Vincent A
- Pao, William
- Freiwald, Matthias
- Fan, Jean
- Wang, Bushi
- Chand, Vikram K
- Groen, Harry J M
Producer: 20180625
In:
Lung cancer (Amsterdam, Netherlands) vol. 113
Availability: No items available.
|
|
|
7.
|
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. [electronic resource] by
- Janjigian, Yelena Y
- Smit, Egbert F
- Groen, Harry J M
- Horn, Leora
- Gettinger, Scott
- Camidge, D Ross
- Riely, Gregory J
- Wang, Bushi
- Fu, Yali
- Chand, Vikram K
- Miller, Vincent A
- Pao, William
Producer: 20160602
In:
Cancer discovery vol. 4
Availability: No items available.
|
|
|
8.
|
Phase 2 trial of afatinib, an ErbB family blocker, in solid tumors genetically screened for target activation. [electronic resource] by
- Kwak, Eunice L
- Shapiro, Geoffrey I
- Cohen, Seth M
- Becerra, Carlos R
- Lenz, Heinz-Josef
- Cheng, Wen-Fang
- Su, Wu-Chou
- Robohn, Meghan
- Le Maulf, Florence
- Lobmeyer, Maximilian T
- Chand, Vikram K
- Iafrate, A John
Producer: 20140225
In:
Cancer vol. 119
Availability: No items available.
|
|
|
9.
|
Afatinib versus erlotinib as second-line treatment of patients with advanced squamous cell carcinoma of the lung (LUX-Lung 8): an open-label randomised controlled phase 3 trial. [electronic resource] by
- Soria, Jean-Charles
- Felip, Enriqueta
- Cobo, Manuel
- Lu, Shun
- Syrigos, Konstantinos
- Lee, Ki Hyeong
- Göker, Erdem
- Georgoulias, Vassilis
- Li, Wei
- Isla, Dolores
- Guclu, Salih Z
- Morabito, Alessandro
- Min, Young J
- Ardizzoni, Andrea
- Gadgeel, Shirish M
- Wang, Bushi
- Chand, Vikram K
- Goss, Glenwood D
Producer: 20151027
In:
The Lancet. Oncology vol. 16
Availability: No items available.
|
|
|
10.
|
Efficacy and Safety of Avelumab for Patients With Recurrent or Refractory Ovarian Cancer: Phase 1b Results From the JAVELIN Solid Tumor Trial. [electronic resource] by
- Disis, Mary L
- Taylor, Matthew H
- Kelly, Karen
- Beck, J Thaddeus
- Gordon, Michael
- Moore, Kathleen M
- Patel, Manish R
- Chaves, Jorge
- Park, Haeseong
- Mita, Alain C
- Hamilton, Erika P
- Annunziata, Christina M
- Grote, Hans Juergen
- von Heydebreck, Anja
- Grewal, Jaspreet
- Chand, Vikram
- Gulley, James L
Producer: 20191219
In:
JAMA oncology vol. 5
Availability: No items available.
|
|
|
11.
|
Avelumab (anti-PD-L1) as first-line switch-maintenance or second-line therapy in patients with advanced gastric or gastroesophageal junction cancer: phase 1b results from the JAVELIN Solid Tumor trial. [electronic resource] by
- Chung, Hyun Cheol
- Arkenau, Hendrik-Tobias
- Lee, Jeeyun
- Rha, Sun Young
- Oh, Do-Youn
- Wyrwicz, Lucjan
- Kang, Yoon-Koo
- Lee, Keun-Wook
- Infante, Jeffrey R
- Lee, Sung Sook
- Kemeny, Margaret
- Keilholz, Ulrich
- Melichar, Bohuslav
- Mita, Alain
- Plummer, Ruth
- Smith, Denis
- Gelb, Arnold B
- Xiong, Huiling
- Hong, Janet
- Chand, Vikram
- Safran, Howard
Producer: 20200331
In:
Journal for immunotherapy of cancer vol. 7
Availability: No items available.
|
|
|
12.
|
Durvalumab With or Without Tremelimumab vs Standard Chemotherapy in First-line Treatment of Metastatic Non-Small Cell Lung Cancer: The MYSTIC Phase 3 Randomized Clinical Trial. [electronic resource] by
- Rizvi, Naiyer A
- Cho, Byoung Chul
- Reinmuth, Niels
- Lee, Ki Hyeong
- Luft, Alexander
- Ahn, Myung-Ju
- van den Heuvel, Michel M
- Cobo, Manuel
- Vicente, David
- Smolin, Alexey
- Moiseyenko, Vladimir
- Antonia, Scott J
- Le Moulec, Sylvestre
- Robinet, Gilles
- Natale, Ronald
- Schneider, Jeffrey
- Shepherd, Frances A
- Geater, Sarayut Lucien
- Garon, Edward B
- Kim, Edward S
- Goldberg, Sarah B
- Nakagawa, Kazuhiko
- Raja, Rajiv
- Higgs, Brandon W
- Boothman, Anne-Marie
- Zhao, Luping
- Scheuring, Urban
- Stockman, Paul K
- Chand, Vikram K
- Peters, Solange
Producer: 20210104
In:
JAMA oncology vol. 6
Availability: No items available.
|